市場調査レポート

商品コード

注射用ドラッグデリバリーの世界市場：製品別、剤形パッケージング別、治療用途別、使用パターン別、投与部位別、エンドユーザー別、地域別 - 2030年までの予測

Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030

出版日: 2025年05月09日
発行: MarketsandMarkets
ページ情報: 英文 967 Pages
納期: 即納可能

カスタマイズ可能

価格

PDF (Single User License)

USD 4,950 718,047円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (5-user License)

USD 6,650 964,649円

レポートPDFを同じ国内の同じ事業所内の5名迄にて共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Corporate License)

USD 8,150 1,182,239円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありませんが、同一国内にある事業所のみとなり、海外支店などは含まれません。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Global License)

USD 10,000 1,450,600円

レポートPDFを同一企業の全世界の方にご使用頂けるライセンスです。ご利用人数に制限はありません。100％子会社は同一企業とみなされます。PDF内のテキスト等のコピー＆ペースト可能です。PDの印刷は何回でも可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

注射用ドラッグデリバリーデバイスの市場規模は、2025年の2,563億米ドルから2030年には3,737億米ドルに達すると予測され、予測期間中のCAGRは7.8%になるとみられています。

注射用ドラッグデリバリー製剤市場は、2025年の4,340億米ドルから2030年には6,611億米ドルに達すると予測され、予測期間中のCAGRは8.8%です。

調査範囲
調査対象年	2024年～2030年
基準年	2024年
予測期間	2024年～2030年
検討単位	金額（10億米ドル）
セグメント別	製品別、剤形パッケージング別、治療用途別、使用パターン別、投与部位別、エンドユーザー別、地域別
対象地域	北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

注射用ドラッグデリバリー市場は、患者中心の、標的を絞った、低侵襲の治療ソリューションに対する需要の高まりにより、急速な変貌を遂げています。この市場の大きな動向は、自動注射器、ペン型注射器、ウェアラブル注射器などの自己注射技術へのシフトです。これらの進歩は患者のコンプライアンスを向上させ、糖尿病、関節リウマチ、多発性硬化症などの慢性疾患を管理する上で特に重要な在宅ケアを容易にします。

技術の進歩はますます市場を形成しつつあります。接続機能、投与量追跡、リマインダーシステムを備えたスマートインジェクターは、デジタルヘルスケアへの広範な動向を反映し、普及が進んでいます。さらに、マイクロニードルや無針注射器の統合は、特に小児や老年層にとって、従来の注射器にしばしば伴う痛みや不安の軽減に役立っています。

製薬業界では、長時間作用型製剤、生物学的製剤、バイオシミラーへの注目が高まっており、正確な送達システムが必要とされています。この動向は、医薬品開発者と機器メーカーとの緊密な連携を促進しています。さらに、規制機関は、配合剤をよりよくサポートするためにその枠組みを更新しており、これは製品承認の迅速化に役立っています。

2025年から2030年にかけて、注射薬デリバリー市場内では自己注射デバイス分野が最も高い成長率を示すと予測されます。この成長の原動力は、世界の分散型医療へのシフト、慢性疾患の有病率の上昇、患者の自律性の重視の高まりです。自己注射器には、自動注射器、ペン型注射器、ウェアラブル注射器などがあり、臨床環境の必要性を減らしながら利便性と精度を提供します。そのため、特に長期間の治療に適しています。

米国とカナダでは、自己免疫疾患や代謝性疾患の治療に生物学的製剤の採用率が高いことに加え、有利な償還政策やヘルスケアにおけるデジタル技術の統合が成長の原動力となっています。欧州、特にドイツ、フランス、英国では、高齢者人口の拡大や慢性疾患管理プログラムの整備により、需要が大幅に増加しています。アジア太平洋では、日本、中国、インドなどの国々が、医療アクセスの改善、患者の意識の向上、バイオシミラーの利用可能性の増加により、急速な成長を遂げています。

スマートコネクティビティ機能、投与量メモリー、疼痛軽減技術などの技術動向が、機器の魅力を高めています。COVID-19の大流行も、患者が病院を避け、自宅での治療を好む傾向にあることから、セルフケアの採用を加速させています。製薬会社と機器メーカーとのコラボレーションも増加しており、注射療法のカスタマイズソリューションが可能となっています。全体として、このセグメントの急成長は、臨床ニーズ、患者の嗜好、技術の進歩の強力な組み合わせを反映しています。

アンプルセグメントは、2024年の注射用ドラッグデリバリー市場内の市場シェアに大きく貢献しました。アンプルは、優れた無菌性、手頃な価格、幅広い薬剤製剤への適応性により、この市場で最も急成長している包装分野です。一般的にガラス製またはプラスチック製のアンプルは、汚染のリスクなしに単回投与注射液を保存するのに理想的であり、急性期医療や病院環境で非常に好まれています。

インド、ブラジル、ベトナムのような新興経済諸国では、アンプルは費用対効果に優れているため、政府の予防接種・接種プログラムで広く使用されています。さらに、様々な生物製剤や低分子医薬品との互換性が、腫瘍学、抗感染症薬、ホルモン療法などの治療分野での採用を促進しています。

アジア太平洋は、人口動態、経済、ヘルスケアなどの要因が重なり、注射剤ドラッグデリバリー市場で最も急成長している地域になりつつあります。中国やインドのような大国では、慢性疾患、特に糖尿病やがんの有病率が上昇しており、高度な注射療法に対する需要が高まっています。さらに、生物製剤へのアクセスが拡大するにつれて、自動注射器やペン型注射器のような使い勝手の良い器具へのニーズが高まっています。

中国では、政府の支援政策、研究開発投資の増加、バイオテクノロジー部門の隆盛が、革新的なドラッグデリバリーシステムの採用を促進しています。一方、ジェネリック医薬品市場の成長を追い風に、インドでも自己注射器やバイオシミラーが大きく成長しています。さらに、ベトナムやタイなどの東南アジア諸国では、医療インフラが整備され、専門医療へのアクセスが向上しており、この地域の需要を押し上げています。

都市化、可処分所得の増加、高齢化も、患者や医療提供者が便利な在宅治療の選択肢を求める傾向に拍車をかけています。さらに、地域の製造能力と費用対効果の高い生産が、世界の製薬会社や医療機器メーカーの提携を引き付けています。

当レポートでは、注射用ドラッグデリバリー市場を製品、治療用途、製剤、パッケージング、使用パターン、投与部位、エンドユーザー、地域別に調査しています。また、市場成長に影響を与える要因（市場促進要因・課題）についても調査しています。市場における機会と課題を分析し、市場リーダーの競合情勢の詳細を提供しています。さらに、個々の成長動向に関してミクロ市場を分析し、主要6地域とそれぞれの国に関して市場セグメントの収益を予測しています。

当レポートは、既存企業と新規または小規模企業の両方が市場動向を理解するのに役立ち、より大きな市場シェアを獲得するのに役立ちます。本レポートを購入された企業は、以下の5つの戦略のうち1つ以上を活用することができます。

市場力学
業界動向
顧客ビジネスに影響を与える動向/混乱
価格分析
バリューチェーン分析
サプライチェーン分析
エコシステム分析
投資と資金調達のシナリオ
技術分析
特許分析
貿易分析
2025年～2026年の主な会議とイベント
ケーススタディ分析
規制状況
ポーターのファイブフォース分析
主要な利害関係者と購入基準
パイプライン分析
償還分析
アンメットニーズ/エンドユーザーの期待
注射用ドラッグデリバリー市場におけるAI/生成AIの影響
2025年の米国関税の影響

第6章注射用ドラッグデリバリー市場、製品別

イントロダクション
デバイス
製剤

第7章注射用ドラッグデリバリー市場、剤形パッケージング別

イントロダクション
アンプル
バイアル
カートリッジ
ボトル

第8章注射用ドラッグデリバリー市場、治療用途別

イントロダクション
自己免疫疾患
ホルモン障害
肥満
がん
感染症
希少疾患
その他

第9章注射用ドラッグデリバリー市場、使用パターン別

イントロダクション
治療ケア
免疫
その他

第10章注射用ドラッグデリバリー市場、投与部位別

イントロダクション
経皮投与
循環器系/筋骨格系に基づく投与
臓器ベースの投与
中枢神経系に基づく投与

第11章注射用ドラッグデリバリー市場、エンドユーザー別

イントロダクション
病院とクリニック
在宅ケア
長期療養環境
介護施設
その他

第12章注射用ドラッグデリバリー市場、地域別

イントロダクション
北米
- 北米のマクロ経済見通し
- 米国
- カナダ
欧州
- 欧州のマクロ経済見通し
- ドイツ
- 英国
- フランス
- スペイン
- イタリア
- オランダ
- その他
アジア太平洋
- アジア太平洋のマクロ経済見通し
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- タイ
- ベトナム
- その他
ラテンアメリカ
- ラテンアメリカのマクロ経済見通し
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 中東・アフリカのマクロ経済見通し
- GCC諸国
- その他

第13章競合情勢

概要
主要参入企業の戦略/強み
収益分析、2020年～2024年
市場シェア分析、2024年
ブランド/製品比較
主要企業の研究開発費
企業評価と財務指標
注射用ドラッグデリバリーデバイス市場：企業評価マトリックス（主要企業）、2024年
注射用ドラッグデリバリーデバイス市場：企業評価マトリックス（スタートアップ/中小企業）、2024年
注射用ドラッグデリバリー製剤市場：企業評価マトリックス（主要企業）、2024年
注射用ドラッグデリバリー製剤市場：企業評価マトリックス（スタートアップ/中小企業）、2023年
競合シナリオ

第14章企業プロファイル：注射用ドラッグデリバリーデバイスメーカー

主要参入企業
- CARDINAL HEALTH
- BD
- B. BRAUN SE
- BAXTER
- TERUMO CORPORATION
- PHILLIPS-MEDSIZE CORPORATION（MOLEX）
- NIPRO
- ICU MEDICAL, INC.
- WEST PHARMACEUTICAL SERVICES, INC.
- GERRESHEIMER AG
- STEVANATO
- SCHOTT PHARMA
- MEDMIX
- SOLM
- YPSOMED
その他の企業
- OWEN MUMFORD
- HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
- POLYMEDICURE
- UNION MEDICO INC.
- SHL MEDICAL
- ELCAM MEDICAL

第15章企業プロファイル：注射用ドラッグデリバリー製剤メーカー

主要参入企業
- JOHNSON & JOHNSON SERVICES, INC.
- F. HOFFMANN-LA ROCHE LTD
- PFIZER INC.
- MERCK & CO., INC.
- NOVARTIS AG
- BAYER AG
- ASTRAZENECA
- TAKEDA PHARMACEUTICAL COMPANY LIMITED.
- ELI LILLY AND COMPANY
- AMGEN INC.
- NOVO NORDISK A/S
- REGENERON PHARMACEUTICALS INC.
- FRESENIUS KABI AG
- UCB S.A.
- BIO-THERA SOLUTIONS, LTD.
その他の企業
- SAGENT
- VALNEVA SE
- XERIS PHARMACEUTICALS, INC.
- PHARMAESSENTIA CORPORATION
- HERON THERAPEUTICS, INC.

第16章付録

図表

List of Tables

TABLE 1 INJECTABLE DRUG DELIVERY MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD), 2021-2024
TABLE 3 INJECTABLE DRUG DELIVERY MARKET: STUDY ASSUMPTIONS
TABLE 4 INJECTABLE DRUG DELIVERY MARKET: RISK ASSESSMENT
TABLE 5 APPROVALS FOR AUTOINJECTOR BIOLOGICS BY US FDA, 2024
TABLE 6 KEY DEVELOPMENTS IN PREFILLED SYRINGES AND PEN INJECTORS, 2024-2025
TABLE 7 KEY BIOSIMILARS/GENERICS WITH INJECTABLE DRUG DELIVERY DEVICES
TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PLAYER, BY DEVICE TYPE, 2022-2024 (USD)
TABLE 9 AVERAGE SELLING PRICE TREND OF PEN INJECTORS, BY REGION, 2022-2024 (USD)
TABLE 10 AVERAGE SELLING PRICE TREND OF NEEDLE-FREE INJECTORS, BY REGION, 2022-2024 (USD)
TABLE 11 AVERAGE SELLING PRICE TREND OF AUTOINJECTORS, BY REGION, 2022-2024 (USD)
TABLE 12 AVERAGE SELLING PRICE TREND OF WEARABLE INJECTORS, BY REGION, 2022-2024 (USD)
TABLE 13 INJECTABLE DRUG DELIVERY DEVICE PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 14 INJECTABLE DRUG DELIVERY FORMULATION PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 15 INJECTABLE DRUG DELIVERY MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023-2025
TABLE 16 IMPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021-2024 (USD THOUSAND)
TABLE 17 EXPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021-2024 (USD THOUSAND)
TABLE 18 IMPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES), BY COUNTRY, 2021-2024 (USD THOUSAND)
TABLE 19 EXPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES), BY COUNTRY, 2021-2024 (USD THOUSAND)
TABLE 20 INJECTABLE DRUG DELIVERY MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
TABLE 21 CASE STUDY 1: DEVELOPMENT OF CLASS III DRUG DELIVERY SYSTEM FOR CHEMOTHERAPY
TABLE 22 CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION
TABLE 23 CASE STUDY 3: ADOPTION OF PEN INJECTOR PLATFORMS FOR IMPROVED THERAPEUTIC OUTCOMES
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 30 INJECTABLE DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 31 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
TABLE 32 INJECTABLE DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE, 2023-2027
TABLE 33 US ADJUSTED RECIPROCAL TARIFF RATES, 2024
TABLE 34 KEY PRODUCT-RELATED TARIFF EFFECTIVE INJECTABLE DRUG DELIVERY DEVICES
TABLE 35 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
TABLE 36 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
TABLE 37 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS
TABLE 38 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
TABLE 39 INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 40 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 41 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY DEVICES
TABLE 42 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 43 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 44 KEY PLAYERS PROVIDING CONVENTIONAL INJECTION DEVICES
TABLE 45 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
TABLE 46 CONVENTIONAL INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 47 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 48 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 49 KEY PLAYERS PROVIDING GLASS INJECTABLE DEVICES
TABLE 50 GLASS INJECTABLE DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 51 KEY PLAYERS PROVIDING PLASTIC INJECTABLE DEVICES
TABLE 52 PLASTIC INJECTABLE DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 53 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 54 KEY PLAYERS PROVIDING FILLABLE SYRINGES
TABLE 55 FILLABLE SYRINGES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 56 KEY PLAYERS PROVIDING PREFILLED SYRINGES
TABLE 57 PREFILLED SYRINGES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 58 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 59 KEY PLAYERS PROVIDING REUSABLE INJECTION DEVICES
TABLE 60 REUSABLE INJECTABLE DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 61 KEY PLAYERS PROVIDING DISPOSABLE INJECTION DEVICES
TABLE 62 DISPOSABLE INJECTABLE DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 63 KEY PLAYERS PROVIDING SELF-INJECTION DEVICES
TABLE 64 SELF-INJECTION DEVICES MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
TABLE 65 SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 66 SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 67 KEY PLAYERS PROVIDING NEEDLE-FREE INJECTORS
TABLE 68 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
TABLE 69 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 70 NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 71 KEY PLAYERS PROVIDING FILLABLE NEEDLE-FREE INJECTORS
TABLE 72 FILLABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 73 KEY PLAYERS PROVIDING PREFILLED NEEDLE-FREE INJECTORS
TABLE 74 PREFILLED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 75 NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 76 KEY PLAYERS PROVIDING JET-BASED NEEDLE-FREE INJECTORS
TABLE 77 JET-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 78 KEY PLAYERS PROVIDING SPRING-BASED NEEDLE-FREE INJECTORS
TABLE 79 SPRING-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 80 KEY PLAYERS PROVIDING LASER-POWERED NEEDLE-FREE INJECTORS
TABLE 81 LASER-POWERED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 82 VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 83 NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 84 KEY PLAYERS PROVIDING REUSABLE NEEDLE-FREE INJECTORS
TABLE 85 REUSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 86 KEY PLAYERS PROVIDING DISPOSABLE NEEDLE-FREE INJECTORS
TABLE 87 DISPOSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 88 KEY PLAYERS PROVIDING AUTOINJECTORS
TABLE 89 AUTOINJECTORS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
TABLE 90 AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 91 AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 92 KEY PLAYERS PROVIDING FILLABLE AUTOINJECTORS
TABLE 93 FILLABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 94 KEY PLAYERS PROVIDING PREFILLED AUTOINJECTORS
TABLE 95 PREFILLED AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 96 AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 97 KEY PLAYERS PROVIDING AUTOMATED AUTOINJECTORS
TABLE 98 AUTOMATED AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 99 KEY PLAYERS PROVIDING MANUAL AUTOINJECTORS
TABLE 100 MANUAL AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 101 AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 102 KEY PLAYERS PROVIDING STANDARDIZED AUTOINJECTORS
TABLE 103 STANDARDIZED AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 104 KEY PLAYERS PROVIDING CUSTOMIZED AUTOINJECTORS
TABLE 105 CUSTOMIZED AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 106 AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 107 KEY PLAYERS PROVIDING REUSABLE AUTOINJECTORS
TABLE 108 REUSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 109 KEY PLAYERS PROVIDING DISPOSABLE AUTOINJECTORS
TABLE 110 DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 111 KEY PLAYERS PROVIDING PEN INJECTORS
TABLE 112 PEN INJECTORS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
TABLE 113 PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 114 PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 115 KEY PLAYERS PROVIDING SINGLE-CHAMBERED PEN INJECTORS
TABLE 116 SINGLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 117 KEY PLAYERS PROVIDING DOUBLE-CHAMBERED PEN INJECTORS
TABLE 118 DOUBLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 119 PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 120 KEY PLAYERS PROVIDING STANDARD PEN INJECTORS
TABLE 121 STANDARD PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 122 KEY PLAYERS PROVIDING CUSTOMIZED PEN INJECTORS
TABLE 123 CUSTOMIZED PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 124 PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 125 KEY PLAYERS PROVIDING REUSABLE PEN INJECTORS
TABLE 126 REUSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 127 KEY PLAYERS PROVIDING DISPOSABLE PEN INJECTORS
TABLE 128 DISPOSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 129 KEY PLAYERS PROVIDING WEARABLE INJECTORS
TABLE 130 WEARABLE INJECTORS MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
TABLE 131 WEARABLE INJECTORS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 132 KEY PLAYERS PROVIDING OTHER SELF-INJECTION DEVICES
TABLE 133 OTHER SELF-INJECTION DEVICES MARKET, BY REGION, 2023-2030 (THOUSAND UNITS)
TABLE 134 OTHER SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 135 KEY PLAYERS PROVIDING FORMULATIONS
TABLE 136 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 137 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 138 KEY PLAYERS PROVIDING CONVENTIONAL DRUG DELIVERY FORMULATIONS
TABLE 139 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 140 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 141 KEY PLAYERS PROVIDING SOLUTIONS
TABLE 142 INJECTABLE DRUG DELIVERY SOLUTIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 143 KEY PLAYERS PROVIDING RECONSTITUTED/LYOPHILIZED FORMULATIONS
TABLE 144 RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 145 KEY PLAYERS PROVIDING SUSPENSIONS
TABLE 146 INJECTABLE DRUG DELIVERY SUSPENSIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 147 KEY PLAYERS PROVIDING EMULSIONS
TABLE 148 INJECTABLE DRUG DELIVERY EMULSIONS MARKET, BY REGION, 2023-2030 (USD BILLION)
TABLE 149 KEY PLAYERS PROVIDING NOVEL DRUG DELIVERY FORMULATIONS
TABLE 150 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 151 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 152 KEY PLAYERS PROVIDING COLLOIDAL DISPERSIONS
TABLE 153 COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 154 COLLOIDAL DISPERSIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 155 INJECTABLE DRUG DELIVERY NIOSOMES MARKET, BY REGION, 2023-2030 (USD BILLION)
TABLE 156 KEY PLAYERS PROVIDING LIPOSOMES
TABLE 157 INJECTABLE DRUG DELIVERY LIPOSOMES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 158 KEY PLAYERS PROVIDING POLYMERIC/MIXED MICELLES
TABLE 159 INJECTABLE DRUG DELIVERY POLYMERIC/MIXED MICELLES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 160 INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 161 INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 162 KEY PLAYERS PROVIDING SOLID-LIPID NANOPARTICLES
TABLE 163 INJECTABLE DRUG DELIVERY SOLID-LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 164 KEY PLAYERS PROVIDING NANOSUSPENSIONS
TABLE 165 INJECTABLE DRUG DELIVERY NANOSUSPENSIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 166 KEY PLAYERS PROVIDING NANOEMULSIONS
TABLE 167 INJECTABLE DRUG DELIVERY NANOEMULSIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 168 KEY PLAYERS PROVIDING MICROPARTICLES
TABLE 169 INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 170 INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 171 KEY PLAYERS PROVIDING MICROSPHERES
TABLE 172 INJECTABLE DRUG DELIVERY MICROSPHERES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 173 KEY PLAYERS PROVIDING MICROCAPSULES
TABLE 174 INJECTABLE DRUG DELIVERY MICROCAPSULES MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 175 KEY PLAYERS PROVIDING LONG-ACTING FORMULATIONS
TABLE 176 LONG-ACTING INJECTABLE FORMULATIONS MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 177 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 178 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 179 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 180 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 181 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 182 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 183 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AUTOIMMUNE DISEASES
TABLE 184 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 185 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 186 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR RHEUMATOID ARTHRITIS
TABLE 187 INJECTABLE DRUG DELIVERY MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 188 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR MULTIPLE SCLEROSIS
TABLE 189 INJECTABLE DRUG DELIVERY MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 190 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR CROHN'S DISEASE
TABLE 191 INJECTABLE DRUG DELIVERY MARKET FOR CROHN'S DISEASE, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 192 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PSORIASIS
TABLE 193 INJECTABLE DRUG DELIVERY MARKET FOR PSORIASIS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 194 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OTHER AUTOIMMUNE DISEASES
TABLE 195 INJECTABLE DRUG DELIVERY MARKET FOR OTHER AUTOIMMUNE DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 196 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HORMONAL DISORDERS
TABLE 197 INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 198 INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 199 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR DIABETES
TABLE 200 INJECTABLE DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 201 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR REPRODUCTIVE HEALTH DISEASES
TABLE 202 INJECTABLE DRUG DELIVERY MARKET FOR REPRODUCTIVE HEALTH DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 203 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
TABLE 204 INJECTABLE DRUG DELIVERY MARKET FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 205 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OSTEOPOROSIS
TABLE 206 INJECTABLE DRUG DELIVERY MARKET FOR OSTEOPOROSIS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 207 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR GROWTH HORMONE DEFICIENCY
TABLE 208 INJECTABLE DRUG DELIVERY MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 209 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OBESITY
TABLE 210 INJECTABLE DRUG DELIVERY MARKET FOR OBESITY, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 211 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR CANCER
TABLE 212 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 213 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR INFECTIOUS DISEASES
TABLE 214 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 215 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ORPHAN DISEASES
TABLE 216 INJECTABLE DRUG DELIVERY MARKET FOR ORPHAN DISEASES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 217 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OTHER THERAPEUTIC APPLICATIONS
TABLE 218 INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 219 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PAIN MANAGEMENT
TABLE 220 INJECTABLE DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 221 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ALLERGIES
TABLE 222 INJECTABLE DRUG DELIVERY MARKET FOR ALLERGIES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 223 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AESTHETIC TREATMENTS
TABLE 224 INJECTABLE DRUG DELIVERY MARKET FOR AESTHETIC TREATMENTS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 225 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HEPATITIS C
TABLE 226 INJECTABLE DRUG DELIVERY MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 227 KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HEMOPHILIA
TABLE 228 INJECTABLE DRUG DELIVERY MARKET FOR HEMOPHILIA, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 229 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 230 INJECTABLE DRUG DELIVERY MARKET FOR CURATIVE CARE, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 231 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNIZATION, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 232 INJECTABLE DRUG DELIVERY MARKET FOR OTHER USAGE PATTERNS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 233 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 234 KEY PLAYERS PROVIDING DERMAL-BASED ADMINISTRATION
TABLE 235 INJECTABLE DRUG DELIVERY MARKET FOR DERMAL-BASED ADMINISTRATION, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 236 KEY PLAYERS PROVIDING CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
TABLE 237 INJECTABLE DRUG DELIVERY MARKET FOR CIRCULATORY/MUSCULOSKELETAL-BASED ADMINISTRATION, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 238 KEY PLAYERS PROVIDING ORGAN-BASED ADMINISTRATION
TABLE 239 INJECTABLE DRUG DELIVERY MARKET FOR ORGAN-BASED ADMINISTRATION, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 240 KEY PLAYERS PROVIDING CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
TABLE 241 INJECTABLE DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 242 INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 243 INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 244 INJECTABLE DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 245 INJECTABLE DRUG DELIVERY MARKET FOR LONG-TERM CARE SETTINGS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 246 INJECTABLE DRUG DELIVERY MARKET FOR NURSING HOMES, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 247 INJECTABLE DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 248 INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
TABLE 249 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 250 NORTH AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 251 NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 252 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 253 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 254 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 255 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 256 NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 257 NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 258 NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 259 NORTH AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 260 NORTH AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 261 NORTH AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 262 NORTH AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 263 NORTH AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 264 NORTH AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 265 NORTH AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 266 NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 267 NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 268 NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 269 NORTH AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 270 NORTH AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 271 NORTH AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 272 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 273 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 274 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 275 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 276 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 277 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 278 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 279 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 280 US: KEY MACROECONOMIC INDICATORS
TABLE 281 US: INJECTABLE DRUG DELIVERY MARKET PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 282 US: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 283 US: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 284 US: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 285 US: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 286 US: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 287 US: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 288 US: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 289 US: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 290 US: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 291 US: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 292 US: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 293 US: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 294 US: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 295 US: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 296 US: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 297 US: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 298 US: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 299 US: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 300 US: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 301 US: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 302 US: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 303 US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 304 US: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 305 US: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 306 US: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 307 US: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 308 US: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 309 US: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 310 US: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 311 CANADA: KEY MACROECONOMIC INDICATORS
TABLE 312 CANADA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 313 CANADA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 314 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 315 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 316 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 317 CANADA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 318 CANADA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 319 CANADA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 320 CANADA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 321 CANADA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 322 CANADA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 323 CANADA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 324 CANADA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 325 CANADA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 326 CANADA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 327 CANADA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 328 CANADA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 329 CANADA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 330 CANADA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 331 CANADA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 332 CANADA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 333 CANADA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 334 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 335 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 336 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 337 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 338 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 339 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 340 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 341 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 342 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 343 EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 344 EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 345 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 346 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 347 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 348 EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 349 EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 350 EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 351 EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 352 EUROPE: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 353 EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 354 EUROPE: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 355 EUROPE: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 356 EUROPE: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 357 EUROPE: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 358 EUROPE: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 359 EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 360 EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 361 EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 362 EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 363 EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 364 EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 365 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 366 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 367 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 368 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 369 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 370 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 371 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 372 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 373 GERMANY: KEY MACROECONOMIC INDICATORS
TABLE 374 GERMANY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 375 GERMANY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 376 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 377 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 378 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 379 GERMANY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 380 GERMANY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 381 GERMANY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 382 GERMANY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 383 GERMANY: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 384 GERMANY: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 385 GERMANY: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 386 GERMANY: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 387 GERMANY: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 388 GERMANY: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 389 GERMANY: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 390 GERMANY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 391 GERMANY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 392 GERMANY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 393 GERMANY: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 394 GERMANY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 395 GERMANY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 396 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 397 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 398 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 399 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 400 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 401 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 402 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 403 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 404 UK: KEY MACROECONOMIC INDICATORS
TABLE 405 UK: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 406 UK: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 407 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 408 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 409 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 410 UK: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 411 UK: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 412 UK: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 413 UK: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 414 UK: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 415 UK: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 416 UK: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 417 UK: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 418 UK: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 419 UK: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 420 UK: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 421 UK: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 422 UK: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 423 UK: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 424 UK: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 425 UK: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 426 UK: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 427 UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 428 UK: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 429 UK: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 430 UK: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 431 UK: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 432 UK: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 433 UK: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 434 UK: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 435 FRANCE: KEY MACROECONOMIC INDICATORS
TABLE 436 FRANCE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 437 FRANCE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 438 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 439 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 440 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 441 FRANCE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 442 FRANCE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 443 FRANCE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 444 FRANCE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 445 FRANCE: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 446 FRANCE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 447 FRANCE: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 448 FRANCE: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 449 FRANCE: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 450 FRANCE: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 451 FRANCE: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 452 FRANCE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 453 FRANCE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 454 FRANCE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 455 FRANCE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 456 FRANCE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 457 FRANCE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 458 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 459 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 460 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 461 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 462 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 463 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 464 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 465 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 466 SPAIN: KEY MACROECONOMIC INDICATORS
TABLE 467 SPAIN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 468 SPAIN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 469 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 470 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 471 SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 472 SPAIN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 473 SPAIN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 474 SPAIN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 475 SPAIN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 476 SPAIN: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 477 SPAIN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 478 SPAIN: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 479 SPAIN: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 480 SPAIN: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 481 SPAIN: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 482 SPAIN: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 483 SPAIN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 484 SPAIN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 485 SPAIN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 486 SPAIN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 487 SPAIN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 488 SPAIN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 489 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 490 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 491 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 492 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 493 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 494 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 495 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 496 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 497 ITALY: KEY MACROECONOMIC INDICATORS
TABLE 498 ITALY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 499 ITALY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 500 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 501 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 502 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 503 ITALY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 504 ITALY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 505 ITALY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 506 ITALY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 507 ITALY: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 508 ITALY: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 509 ITALY: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 510 ITALY: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 511 ITALY: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 512 ITALY: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 513 ITALY: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 514 ITALY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 515 ITALY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 516 ITALY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 517 ITALY: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 518 ITALY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 519 ITALY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 520 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 521 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 522 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 523 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 524 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 525 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 526 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 527 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 528 NETHERLANDS: KEY MACROECONOMIC INDICATORS
TABLE 529 NETHERLANDS: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 530 NETHERLANDS: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 531 NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 532 NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 533 NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 534 NETHERLANDS: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 535 NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 536 NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 537 NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 538 NETHERLANDS: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 539 NETHERLANDS: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 540 NETHERLANDS: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 541 NETHERLANDS: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 542 NETHERLANDS: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 543 NETHERLANDS: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 544 NETHERLANDS: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 545 NETHERLANDS: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 546 NETHERLANDS: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 547 NETHERLANDS: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 548 NETHERLANDS: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 549 NETHERLANDS: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 550 NETHERLANDS: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 551 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 552 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 553 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 554 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 555 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 556 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 557 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 558 NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 559 REST OF EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 560 REST OF EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 561 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 562 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 563 REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 564 REST OF EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 565 REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 566 REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 567 REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 568 REST OF EUROPE: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 569 REST OF EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 570 REST OF EUROPE: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 571 REST OF EUROPE: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 572 REST OF EUROPE: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 573 REST OF EUROPE: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 574 REST OF EUROPE: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 575 REST OF EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 576 REST OF EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 577 REST OF EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 578 REST OF EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 579 REST OF EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 580 REST OF EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 581 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 582 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 583 REST OF EUROPE: INJECTABLE DRUG DELIVERY FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 584 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 585 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 586 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 587 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 588 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 589 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 590 ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 591 ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 592 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 593 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 594 ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 595 ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 596 ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 597 ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 598 ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 599 ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 600 ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 601 ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 602 ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 603 ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 604 ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 605 ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 606 ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 607 ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 608 ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 609 ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 610 ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 611 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 612 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 613 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 614 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 615 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 616 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 617 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 618 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 619 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 620 CHINA: KEY MACROECONOMIC INDICATORS
TABLE 621 CHINA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 622 CHINA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 623 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 624 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 625 CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 626 CHINA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 627 CHINA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 628 CHINA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 629 CHINA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 630 CHINA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 631 CHINA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 632 CHINA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 633 CHINA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 634 CHINA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 635 CHINA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 636 CHINA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 637 CHINA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 638 CHINA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 639 CHINA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 640 CHINA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 641 CHINA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 642 CHINA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 643 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 644 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 645 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 646 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 647 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 648 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 649 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 650 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 651 JAPAN: KEY MACROECONOMIC INDICATORS
TABLE 652 JAPAN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 653 JAPAN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 654 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 655 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 656 JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 657 JAPAN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 658 JAPAN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 659 JAPAN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 660 JAPAN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 661 JAPAN: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 662 JAPAN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 663 JAPAN: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 664 JAPAN: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 665 JAPAN: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 666 JAPAN: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 667 JAPAN: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 668 JAPAN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 669 JAPAN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 670 JAPAN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 671 JAPAN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 672 JAPAN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 673 JAPAN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 674 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 675 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 676 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 677 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 678 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 679 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 680 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 681 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 682 INDIA: KEY MACROECONOMIC INDICATORS
TABLE 683 INDIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 684 INDIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 685 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 686 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 687 INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 688 INDIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 689 INDIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 690 INDIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 691 INDIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 692 INDIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 693 INDIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 694 INDIA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 695 INDIA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 696 INDIA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 697 INDIA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 698 INDIA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 699 INDIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 700 INDIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 701 INDIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 702 INDIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 703 INDIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 704 INDIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 705 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 706 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 707 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 708 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 709 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 710 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 711 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 712 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 713 AUSTRALIA: KEY MACROECONOMIC INDICATORS
TABLE 714 AUSTRALIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 715 AUSTRALIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 716 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 717 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 718 AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 719 AUSTRALIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 720 AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 721 AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 722 AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 723 AUSTRALIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 724 AUSTRALIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 725 AUSTRALIA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 726 AUSTRALIA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 727 AUSTRALIA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 728 AUSTRALIA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 729 AUSTRALIA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 730 AUSTRALIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 731 AUSTRALIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 732 AUSTRALIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 733 AUSTRALIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 734 AUSTRALIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 735 AUSTRALIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 736 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 737 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 738 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 739 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 740 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 741 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 742 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 743 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 744 SOUTH KOREA: KEY MACROECONOMIC INDICATORS
TABLE 745 SOUTH KOREA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, TYPE, 2023-2030 (USD BILLION)
TABLE 746 SOUTH KOREA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 747 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 748 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 749 SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 750 SOUTH KOREA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 751 SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 752 SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 753 SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 754 SOUTH KOREA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 755 SOUTH KOREA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 756 SOUTH KOREA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 757 SOUTH KOREA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 758 SOUTH KOREA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 759 SOUTH KOREA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 760 SOUTH KOREA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 761 SOUTH KOREA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 762 SOUTH KOREA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 763 SOUTH KOREA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 764 SOUTH KOREA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 765 SOUTH KOREA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 766 SOUTH KOREA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 767 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 768 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 769 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 770 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 771 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 772 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 773 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 774 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 775 THAILAND: KEY MACROECONOMIC INDICATORS
TABLE 776 THAILAND: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 777 THAILAND: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 778 THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 779 THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 780 THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 781 THAILAND: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 782 THAILAND: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 783 THAILAND: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 784 THAILAND: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 785 THAILAND: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 786 THAILAND: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 787 THAILAND: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 788 THAILAND: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 789 THAILAND: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 790 THAILAND: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 791 THAILAND: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 792 THAILAND: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 793 THAILAND: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 794 THAILAND: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 795 THAILAND: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 796 THAILAND: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 797 THAILAND: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 798 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 799 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 800 THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 801 THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 802 THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 803 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 804 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 805 THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 806 VIETNAM: KEY MACROECONOMIC INDICATORS
TABLE 807 VIETNAM: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 808 VIETNAM: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 809 VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 810 VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 811 VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 812 VIETNAM: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 813 VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 814 VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 815 VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 816 VIETNAM: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 817 VIETNAM: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 818 VIETNAM: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 819 VIETNAM: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 820 VIETNAM: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 821 VIETNAM: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 822 VIETNAM: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 823 VIETNAM: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 824 VIETNAM: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 825 VIETNAM: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 826 VIETNAM: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 827 VIETNAM: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 828 VIETNAM: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 829 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 830 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 831 VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 832 VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 833 VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 834 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 835 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 836 VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 837 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 838 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 839 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 840 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 841 REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 842 REST OF ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 843 REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 844 REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 845 REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 846 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 847 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 848 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 849 REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 850 REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 851 REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 852 REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 853 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 854 REST OF ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 855 REST OF ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 856 REST OF ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 857 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 858 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 859 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 860 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 861 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 862 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 863 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 864 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 865 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 866 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 867 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 868 LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 869 LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 870 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 871 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 872 LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 873 LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 874 LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 875 LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 876 LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 877 LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 878 LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 879 LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 880 LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 881 LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 882 LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 883 LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 884 LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 885 LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 886 LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 887 LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 888 LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 889 LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 890 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 891 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 892 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 893 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 894 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 895 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 896 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 897 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 898 BRAZIL: KEY MACROECONOMIC INDICATORS
TABLE 899 BRAZIL: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 900 BRAZIL: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 901 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 902 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 903 BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 904 BRAZIL: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 905 BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 906 BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 907 BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 908 BRAZIL: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 909 BRAZIL: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 910 BRAZIL: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 911 BRAZIL: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 912 BRAZIL: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 913 BRAZIL: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 914 BRAZIL: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 915 BRAZIL: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 916 BRAZIL: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 917 BRAZIL: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 918 BRAZIL: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 919 BRAZIL: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 920 BRAZIL: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 921 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 922 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 923 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 924 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 925 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 926 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 927 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 928 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 929 MEXICO: KEY MACROECONOMIC INDICATORS
TABLE 930 MEXICO: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 931 MEXICO: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 932 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 933 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 934 MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 935 MEXICO: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 936 MEXICO: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 937 MEXICO: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 938 MEXICO: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 939 MEXICO: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 940 MEXICO: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 941 MEXICO: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 942 MEXICO: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 943 MEXICO: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 944 MEXICO: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 945 MEXICO: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 946 MEXICO: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 947 MEXICO: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 948 MEXICO: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 949 MEXICO: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 950 MEXICO: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 951 MEXICO: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 952 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 953 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 954 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 955 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 956 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 957 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 958 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 959 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 960 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 961 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 962 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 963 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 964 REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 965 REST OF LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 966 REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 967 REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 968 REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 969 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 970 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 971 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 972 REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 973 REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 974 REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 975 REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 976 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 977 REST OF LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 978 REST OF LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 979 REST OF LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 980 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 981 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 982 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 983 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 984 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 985 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 986 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 987 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 988 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 989 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 990 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023-2030 (USD BILLION)
TABLE 991 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 992 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 993 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 994 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 995 MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 996 MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 997 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 998 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 999 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1000 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1001 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1002 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1003 MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1004 MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1005 MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1006 MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1007 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1008 MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1009 MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1010 MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1011 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1012 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1013 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 1014 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 1015 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1016 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1017 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1018 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 1019 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 1020 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 1021 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023-2030 (USD BILLION)
TABLE 1022 GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1023 GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1024 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 1025 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1026 GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1027 GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1028 GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1029 GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1030 GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1031 GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1032 GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1033 GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1034 GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1035 GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1036 GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1037 GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1038 GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1039 GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1040 GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1041 GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1042 GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1043 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1044 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 1045 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 1046 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1047 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1048 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1049 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 1050 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 1051 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 1052 SAUDI ARABIA: KEY MACROECONOMIC INDICATORS
TABLE 1053 SAUDI ARABIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1054 SAUDI ARABIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1055 SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 1056 SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1057 SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1058 SAUDI ARABIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1059 SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1060 SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1061 SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1062 SAUDI ARABIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1063 SAUDI ARABIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1064 SAUDI ARABIA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1065 SAUDI ARABIA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1066 SAUDI ARABIA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1067 SAUDI ARABIA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1068 SAUDI ARABIA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1069 SAUDI ARABIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1070 SAUDI ARABIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1071 SAUDI ARABIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1072 SAUDI ARABIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1073 SAUDI ARABIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1074 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1075 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 1076 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 1077 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1078 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1079 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1080 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 1081 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 1082 SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 1083 UNITED ARAB EMIRATES (UAE): KEY MACROECONOMIC INDICATORS
TABLE 1084 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1085 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1086 UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 1087 UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1088 UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1089 UNITED ARAB EMIRATES (UAE): SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1090 UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1091 UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1092 UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1093 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1094 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1095 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1096 UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1097 UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1098 UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1099 UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1100 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1101 UNITED ARAB EMIRATES (UAE): CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1102 UNITED ARAB EMIRATES (UAE): NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1103 UNITED ARAB EMIRATES (UAE): COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1104 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1105 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1106 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 1107 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 1108 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1109 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1110 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1111 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 1112 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 1113 UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 1114 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1115 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1116 REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 1117 REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1118 REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1119 REST OF GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1120 REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1121 REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1122 REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1123 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1124 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1125 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1126 REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1127 REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1128 REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1129 REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1130 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1131 REST OF GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1132 REST OF GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1133 REST OF GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1134 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1135 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1136 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 1137 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 1138 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1139 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1140 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1141 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 1142 REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 1143 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 1144 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1145 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1146 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023-2030 (USD BILLION)
TABLE 1147 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1148 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1149 REST OF MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1150 REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1151 REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1152 REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1153 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1154 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023-2030 (USD BILLION)
TABLE 1155 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1156 REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1157 REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT, 2023-2030 (USD BILLION)
TABLE 1158 REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN, 2023-2030 (USD BILLION)
TABLE 1159 REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY, 2023-2030 (USD BILLION)
TABLE 1160 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1161 REST OF MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1162 REST OF MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1163 REST OF MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1164 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1165 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1166 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023-2030 (USD BILLION)
TABLE 1167 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023-2030 (USD BILLION)
TABLE 1168 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1169 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1170 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023-2030 (USD BILLION)
TABLE 1171 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023-2030 (USD BILLION)
TABLE 1172 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023-2030 (USD BILLION)
TABLE 1173 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023-2030 (USD BILLION)
TABLE 1174 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INJECTABLE DRUG DELIVERY MARKET
TABLE 1175 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS: DEGREE OF COMPETITION
TABLE 1176 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION
TABLE 1177 INJECTABLE DRUG DELIVERY DEVICES MARKET: REGION FOOTPRINT
TABLE 1178 INJECTABLE DRUG DELIVERY DEVICES MARKET: PRODUCT TYPE FOOTPRINT
TABLE 1179 INJECTABLE DRUG DELIVERY DEVICES MARKET: USAGE PATTERN FOOTPRINT
TABLE 1180 INJECTABLE DRUG DELIVERY DEVICES MARKET: THERAPEUTIC APPLICATION FOOTPRINT
TABLE 1181 INJECTABLE DRUG DELIVERY DEVICES MARKET: SITE OF ADMINISTRATION FOOTPRINT
TABLE 1182 INJECTABLE DRUG DELIVERY DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 1183 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 1184 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: REGION FOOTPRINT
TABLE 1185 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: PRODUCT TYPE FOOTPRINT
TABLE 1186 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: FORMULATION PACKAGING FOOTPRINT
TABLE 1187 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: THERAPEUTIC APPLICATION FOOTPRINT
TABLE 1188 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: SITE OF ADMINISTRATION TYPE FOOTPRINT
TABLE 1189 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 1190 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 1191 INJECTABLE DRUG DELIVERY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
TABLE 1192 INJECTABLE DRUG DELIVERY MARKET: DEALS, JANUARY 2022-MARCH 2025
TABLE 1193 INJECTABLE DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1194 CARDINAL HEALTH: COMPANY OVERVIEW
TABLE 1195 CARDINAL HEALTH: PRODUCTS OFFERED
TABLE 1196 CARDINAL HEALTH: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1197 BD: COMPANY OVERVIEW
TABLE 1198 BD: PRODUCTS OFFERED
TABLE 1199 BD: DEALS, JANUARY 2022-MARCH 2025
TABLE 1200 BD: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1201 B. BRAUN SE: COMPANY OVERVIEW
TABLE 1202 B. BRAUN SE: PRODUCTS OFFERED
TABLE 1203 BAXTER: COMPANY OVERVIEW
TABLE 1204 BAXTER: PRODUCTS OFFERED
TABLE 1205 BAXTER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
TABLE 1206 TERUMO CORPORATION: COMPANY OVERVIEW
TABLE 1207 TERUMO CORPORATION: PRODUCTS OFFERED
TABLE 1208 TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
TABLE 1209 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1210 PHILLIPS-MEDSIZE CORPORATION (MOLEX): COMPANY OVERVIEW
TABLE 1211 PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCTS OFFERED
TABLE 1212 PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
TABLE 1213 PHILLIPS-MEDSIZE CORPORATION (MOLEX): DEALS, JANUARY 2022-MARCH 2025
TABLE 1214 PHILLIPS-MEDSIZE CORPORATION (MOLEX): EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1215 NIPRO: COMPANY OVERVIEW
TABLE 1216 NIPRO: PRODUCTS OFFERED
TABLE 1217 NIPRO: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1218 ICU MEDICAL, INC.: COMPANY OVERVIEW
TABLE 1219 ICU MEDICAL, INC.: PRODUCTS OFFERED
TABLE 1220 ICU MEDICAL, INC.: DEALS, JANUARY 2022-MARCH 2025
TABLE 1221 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
TABLE 1222 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED
TABLE 1223 WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022-MARCH 2025
TABLE 1224 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1225 GERRESHEIMER AG: COMPANY OVERVIEW
TABLE 1226 GERRESHEIMER AG: PRODUCTS OFFERED
TABLE 1227 GERRESHEIMER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
TABLE 1228 GERRESHMEIMER AG: DEALS, JANUARY 2022-MARCH 2025
TABLE 1229 GERRESHMEIMER AG: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1230 STEVANATO: COMPANY OVERVIEW
TABLE 1231 STEVANATO: PRODUCTS OFFERED
TABLE 1232 STEVANATO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
TABLE 1233 STEVANATO: DEALS, JANUARY 2022-MARCH 2025
TABLE 1234 STEVANATO: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1235 SCHOTT PHARMA: COMPANY OVERVIEW
TABLE 1236 SCHOTT PHARMA: PRODUCTS OFFERED
TABLE 1237 SCHOTT PHARMA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
TABLE 1238 SCHOTT PHARMA: DEALS, JANUARY 2022-MARCH 2025
TABLE 1239 SCOTT PHARMA: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1240 MEDMIX: COMPANY OVERVIEW
TABLE 1241 MEDMIX: PRODUCTS OFFERED
TABLE 1242 MEDMIX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-MARCH 2025
TABLE 1243 MEDMIX: DEALS, JANUARY 2022-APRIL 2025
TABLE 1244 SOLM: COMPANY OVERVIEW
TABLE 1245 SOLM: PRODUCTS OFFERED
TABLE 1246 YPSOMED: COMPANY OVERVIEW
TABLE 1247 YPSOMED: PRODUCTS OFFERED
TABLE 1248 YPSOMED: DEALS, JANUARY 2022-MARCH 2025
TABLE 1249 YPSOMED: EXPANSIONS, JANUARY 2022-MARCH 2025
TABLE 1250 OWEN MUMFORD: COMPANY OVERVIEW
TABLE 1251 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW
TABLE 1252 POLYMEDICURE: COMPANY OVERVIEW
TABLE 1253 UNION MEDICO INC.: COMPANY OVERVIEW
TABLE 1254 SHL MEDICAL: COMPANY OVERVIEW
TABLE 1255 ELCAM MEDICAL: COMPANY OVERVIEW
TABLE 1256 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
TABLE 1257 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
TABLE 1258 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1259 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022-APRIL 2025
TABLE 1260 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 1261 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 1262 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1263 PFIZER INC.: COMPANY OVERVIEW
TABLE 1264 PFIZER INC.: PRODUCTS OFFERED
TABLE 1265 PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1266 PFIZER INC.: DEALS, JANUARY 2022-APRIL 2025
TABLE 1267 MERCK & CO., INC.: COMPANY OVERVIEW
TABLE 1268 MERCK & CO., INC.: PRODUCTS OFFERED
TABLE 1269 MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1270 MERCK & CO., INC.: DEALS, JANUARY 2022-APRIL 2025
TABLE 1271 MERCK & CO., INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
TABLE 1272 NOVARTIS AG: COMPANY OVERVIEW
TABLE 1273 NOVARTIS AG: PRODUCTS OFFERED
TABLE 1274 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1275 NOVARTIS AG: DEALS, JANUARY 2022-APRIL 2025
TABLE 1276 NOVARTIS AG: EXPANSIONS, JANUARY 2022-APRIL 2025
TABLE 1277 BAYER AG: COMPANY OVERVIEW
TABLE 1278 BAYER AG: PRODUCTS OFFERED
TABLE 1279 BAYER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1280 BAYER AG: EXPANSIONS, JANUARY 2022-APRIL 2025
TABLE 1281 ASTRAZENECA: COMPANY OVERVIEW
TABLE 1282 ASTRAZENECA: PRODUCTS OFFERED
TABLE 1283 ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1284 ASTRAZENECA: DEALS, JANUARY 2022-APRIL 2025
TABLE 1285 ASTRAZENECA: EXPANSIONS, JANUARY 2022-APRIL 2025
TABLE 1286 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
TABLE 1287 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
TABLE 1288 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1289 TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2022-APRIL 2025
TABLE 1290 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS, JANUARY 2022-APRIL 2025
TABLE 1291 ELI LILLY AND COMPANY: COMPANY OVERVIEW
TABLE 1292 ELI LILLY AND COMPANY: PRODUCTS OFFERED
TABLE 1293 ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1294 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022-APRIL 2025
TABLE 1295 AMGEN INC.: COMPANY OVERVIEW
TABLE 1296 AMGEN INC.: PRODUCTS OFFERED
TABLE 1297 AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1298 AMGEN INC.: DEALS, JANUARY 2022-APRIL 2025
TABLE 1299 AMGEN INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
TABLE 1300 NOVO NORDISK A/S: COMPANY OVERVIEW
TABLE 1301 NOVO NORDISK A/S: PRODUCTS OFFERED
TABLE 1302 NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1303 NOVO NORDISK A/S: DEALS, JANUARY 2022-APRIL 2025
TABLE 1304 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022-APRIL 2025
TABLE 1305 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
TABLE 1306 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
TABLE 1307 REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1308 REGENERON PHARMACEUTICALS INC.: DEALS, JANUARY 2022-APRIL 2025
TABLE 1309 FRESENIUS KABI AG: COMPANY OVERVIEW
TABLE 1310 FRESENIUS KABI AG: PRODUCTS OFFERED
TABLE 1311 FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1312 UCB S.A.: COMPANY OVERVIEW
TABLE 1313 UCB S.A.: PRODUCTS OFFERED
TABLE 1314 UCB S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1315 BIO-THERA SOLUTIONS, LTD.: COMPANY OVERVIEW
TABLE 1316 BIO-THERA SOLUTIONS, LTD.: PRODUCTS OFFERED
TABLE 1317 BIO-THERA SOLUTIONS, LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-APRIL 2025
TABLE 1318 SAGENT: COMPANY OVERVIEW
TABLE 1319 VALNEVA SE: COMPANY OVERVIEW
TABLE 1320 XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
TABLE 1321 PHARMAESSENTIA CORPORATION: COMPANY OVERVIEW
TABLE 1322 HERON THERAPEUTICS, INC.: COMPANY OVERVIEW

List of Figures

FIGURE 1 INJECTABLE DRUG DELIVERY MARKET SEGMENTATION
FIGURE 2 INJECTABLE DRUG DELIVERY MARKET REGIONAL SEGMENTATION
FIGURE 3 INJECTABLE DRUG DELIVERY MARKET: RESEARCH DESIGN
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
FIGURE 7 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
FIGURE 8 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 BOTTOM-UP APPROACH
FIGURE 11 DATA TRIANGULATION METHODOLOGY
FIGURE 12 INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
FIGURE 13 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2025 VS. 2030 (USD BILLION)
FIGURE 14 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD BILLION)
FIGURE 15 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2025 VS. 2030 (USD BILLION)
FIGURE 16 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
FIGURE 17 INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 18 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT
FIGURE 19 RISING CHRONIC DISEASES TO DRIVE MARKET
FIGURE 20 DEVICES SEGMENT AND US DOMINATED NORTH AMERICAN INJECTABLE DRUG DELIVERY MARKET IN 2024
FIGURE 21 ASIA PACIFIC TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 22 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 23 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
FIGURE 24 INJECTABLE DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 26 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PEN INJECTORS (INSULIN PENS), 2024 (USD)
FIGURE 27 INJECTABLE DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
FIGURE 28 INJECTABLE DRUG DELIVERY MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 29 INJECTABLE DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS
FIGURE 30 INJECTABLE DRUG DELIVERY MARKET: INVESTMENT AND FUNDING SCENARIO, 2021-2023
FIGURE 31 INJECTABLE DRUG DELIVERY MARKET: PATENT ANALYSIS, JANUARY 2014-MARCH 2025
FIGURE 32 TOP APPLICANTS FOR INJECTABLE DRUG DELIVERY PATENTS, JANUARY 2014-MARCH 2025
FIGURE 33 INJECTABLE DRUG DELIVERY MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 34 KEY STAKEHOLDERS IN BUYING PROCESS FOR HOSPITALS & CLINICS (INJECTABLE DRUG DELIVERY DEVICES)
FIGURE 35 BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY DEVICES FOR TOP THREE END USERS
FIGURE 36 KEY BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY WITH FORMULATIONS FOR TOP THREE END USERS
FIGURE 37 TOTAL NUMBER OF TRIALS COMPLETED/YEAR, 2024-2032
FIGURE 38 AI USE CASES
FIGURE 39 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT, 2024
FIGURE 40 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
FIGURE 41 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
FIGURE 42 REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2022-2024
FIGURE 43 REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2022-2024
FIGURE 44 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024
FIGURE 45 RANKING OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024
FIGURE 46 MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2024
FIGURE 47 RANKING OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2024
FIGURE 48 INJECTABLE DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARISON
FIGURE 49 R&D EXPENDITURE OF KEY PLAYERS IN INJECTABLE DRUG DELIVERY MARKET, 2022-2024
FIGURE 50 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 51 YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 52 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 53 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT
FIGURE 54 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 55 INJECTABLE DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX, 2024
FIGURE 56 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT
FIGURE 57 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 58 CARDINAL HEALTH: COMPANY SNAPSHOT (2024)
FIGURE 59 BD: COMPANY SNAPSHOT (2024)
FIGURE 60 B. BRAUN SE: COMPANY SNAPSHOT (2023)
FIGURE 61 BAXTER: COMPANY SNAPSHOT (2024)
FIGURE 62 TERUMO CORPORATION: COMPANY SNAPSHOT (2023)
FIGURE 63 NIPRO: COMPANY SNAPSHOT (2024)
FIGURE 64 ICU MEDICAL, INC.: COMPANY SNAPSHOT (2024)
FIGURE 65 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 66 GERRESHEIMER AG: COMPANY SNAPSHOT (2024)
FIGURE 67 STEVANATO: COMPANY SNAPSHOT (2024)
FIGURE 68 SCHOTT PHARMA: COMPANY SNAPSHOT (2024)
FIGURE 69 MEDMIX: COMPANY SNAPSHOT (2024)
FIGURE 70 YPSOMED: COMPANY SNAPSHOT (2024)
FIGURE 71 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 72 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
FIGURE 73 PFIZER INC.: COMPANY SNAPSHOT (2024)
FIGURE 74 MERCK & CO., INC.: COMPANY SNAPSHOT (2024)
FIGURE 75 NOVARTIS AG: COMPANY SNAPSHOT (2024)
FIGURE 76 BAYER AG: COMPANY SNAPSHOT (2024)
FIGURE 77 ASTRAZENECA: COMPANY SNAPSHOT (2024)
FIGURE 78 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2024)
FIGURE 79 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024)
FIGURE 80 AMGEN INC.: COMPANY SNAPSHOT (2024)
FIGURE 81 NOVO NORDISK A/S: COMPANY SNAPSHOT (2024)
FIGURE 82 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
FIGURE 83 FRESENIUS KABI AG: COMPANY SNAPSHOT (2024)
FIGURE 84 UCB S.A.: COMPANY SNAPSHOT (2024)
FIGURE 85 BIO-THERA SOLUTIONS, LTD.: COMPANY SNAPSHOT (2024)

Product Code: MD 3680

The injectable drug delivery devices market is projected to reach USD 373.7 billion by 2030 from USD 256.3 billion in 2025, at a CAGR of 7.8% during the forecast period. The injectable drug delivery formulations market is projected to reach USD 661.1 billion by 2030 from USD 434.0 billion in 2025, at a CAGR of 8.8% during the forecast period.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2024-2030
Units Considered	Value (USD billion)
Segments	By Product, Therapeutic Application, Therapy Area, Formulation Packaging, Formulation Packaging, Usage Pattern, Site of Administration, End User, Region
Regions covered	North America, Europe, APAC, LATAM, MEA

The injectable drug delivery market is experiencing rapid transformation due to the increasing demand for patient-centric, targeted, and minimally invasive treatment solutions. A significant trend in this market is the shift toward self-injection technologies, which include autoinjectors, pen injectors, and wearable injectors. These advancements enhance patient compliance and facilitate at-home care, which is especially important for managing chronic conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis.

Technological advancements are increasingly shaping the market. Smart injectors equipped with connectivity features, dose tracking, and reminder systems are becoming more popular, reflecting the broader trend toward digital healthcare. Furthermore, the integration of microneedles and needle-free injectors is helping to reduce the pain and anxiety often associated with traditional syringes, particularly for pediatric and geriatric populations.

The pharmaceutical industry increasingly focuses on long-acting formulations, biologics, and biosimilars, requiring precise delivery systems. This trend is fostering closer collaboration between drug developers and device manufacturers. Additionally, regulatory bodies are updating their frameworks to better support combination products, which is helping to accelerate product approvals.

"By device, the self-injection devices segment is projected to grow at the highest CAGR during the forecast period."

From 2025 to 2030, the self-injection devices segment is expected to grow at the highest rate within the injectable drug delivery market. This growth is driven by a global shift toward decentralized care, an increase in the prevalence of chronic diseases, and a growing emphasis on patient autonomy. Self-injection devices, which include autoinjectors, pen injectors, and wearable injectors, provide convenience and precision while reducing the need for clinical settings. This makes them particularly suitable for long-term therapies.

In the US and Canada, growth is driven by a high adoption rate of biologics for treating autoimmune and metabolic disorders, along with favorable reimbursement policies and the integration of digital technology in healthcare. Demand has increased significantly in Europe, particularly Germany, France, and the UK, due to the expanding geriatric population and well-structured chronic disease management programs. In the Asia Pacific region, countries such as Japan, China, and India are experiencing rapid growth due to improved healthcare access, increased patient awareness, and a rise in the availability of biosimilars.

Technological trends such as smart connectivity features, dose memory, and pain-reduction technologies make devices more appealing. The COVID-19 pandemic has also accelerated the adoption of self-care, as patients tend to avoid hospitals and prefer administering treatments at home. Collaborations between pharmaceutical companies and device manufacturers are increasing, allowing for customized solutions for injectable therapies. Overall, the rapid growth of this segment reflects a strong combination of clinical needs, patient preferences, and technological advancements.

"By formulation packaging, the ampoules segment accounted for the largest market share in 2024."

The ampoules segment was the leading contributor to market share within the injectable drug delivery market in 2024. Ampoules are the fastest-growing packaging segment in this market, driven by their superior sterility, affordability, and adaptability to a wide range of drug formulations. Typically made of glass or plastic, ampoules are ideal for preserving single-dose injectable solutions without the risk of contamination, making them highly preferred in acute care and hospital settings.

In developing economies like India, Brazil, and Vietnam, the cost-effectiveness of ampoules encourages their widespread use in government vaccination and immunization programs. Additionally, their compatibility with various biologics and small-molecule drugs further facilitates adoption across therapeutic areas such as oncology, anti-infectives, and hormonal therapies.

"The Asia Pacific (APAC) region is expected to witness the highest growth rate during the forecast period."

The Asia Pacific region is becoming the fastest-growing area in the injectable drug delivery market, driven by a combination of demographic, economic, and healthcare factors. The increasing prevalence of chronic diseases, particularly diabetes and cancer, in large countries like China and India, is creating a greater demand for advanced injectable therapies. Additionally, as access to biologics expands, there is an increased need for user-friendly devices, such as autoinjectors and pen injectors.

In China, supportive government policies, increasing investment in research and development, and a thriving biotechnology sector are driving the adoption of innovative drug delivery systems. Meanwhile, India, benefiting from a growing generics market, is also seeing significant growth in self-injection devices and biosimilars. Additionally, Southeast Asian countries like Vietnam and Thailand are enhancing their healthcare infrastructure and improving access to specialty care, which is boosting regional demand.

Urbanization, increasing disposable incomes, and a growing aging population contribute to the trend as patients and providers seek convenient, home-based treatment options. Additionally, regional manufacturing capabilities and cost-effective production attract partnerships from global pharmaceutical and device firms.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%) * By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%) * By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews: * By Company Type: Hospitals (60%), Ambulatory Surgical Centers (25%), and Home Care Settings (15%) * By Designation: Directors (35%), Vice Presidents (27%), Managers (22%), and Other Designations (16%) * By Region: North America (40%), Europe (25%), APAC (20%), Latin America (10%), and the Middle East & Africa (5%)

Research Coverage

This report studies the injectable drug delivery market based on product, therapeutic application, formulation, packaging, usage pattern, site of administration, end user, and region. The report also studies factors affecting market growth (drivers, restraints, opportunities, and challenges). It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to six main regions and respective countries.

Reasons to Buy the Report

The report can assist both established companies and new or smaller firms understand the market trends, which will help them capture a larger market share. Firms that purchase the report can utilize one or more of the five strategies mentioned below.

This report provides insights into the following points:

Analysis of key drivers (increasing chronic diseases, increasing biologics, and technological advancements), restraints (infections associated with needle-stick injuries), challenges (other methods of injectable drug delivery available in the market), and opportunities (increasing demand for generic medicines and biosimilars) influencing the growth of injectable drug delivery market.
Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the injectable drug delivery market.
Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of injectable drug delivery procedures across regions.
Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the injectable drug delivery market.
Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the injectable drug delivery market.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
- 1.3.1 MARKETS SEGMENTATION
- 1.3.2 REGIONAL SEGMENTATION
- 1.3.3 YEARS CONSIDERED
- 1.3.4 INCLUSIONS AND EXCLUSIONS
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
  - 2.1.1.1 Key secondary sources
- 2.1.2 PRIMARY DATA
  - 2.1.2.1 Primary sources
  - 2.1.2.2 Key data from primary sources
  - 2.1.2.3 Breakdown of primaries
2.2 MARKET SIZE ESTIMATION
- 2.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH
- 2.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
- 2.2.3 APPROACH 3: TOP-DOWN APPROACH
- 2.2.4 APPROACH 4: BOTTOM-UP APPROACH
- 2.2.5 APPROACH 4: PRIMARY INTERVIEWS
- 2.2.6 APPROACH 5: DEMAND-SIDE APPROACH
- 2.2.7 APPROACH 6: VOLUME DATA ANALYSIS
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
2.4 MARKET SHARE ASSESSMENT
2.5 RESEARCH ASSUMPTIONS
- 2.5.1 STUDY ASSUMPTIONS
- 2.5.2 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 INJECTABLE DRUG DELIVERY MARKET OVERVIEW
4.2 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET OVERVIEW
4.3 INJECTABLE DRUG DELIVERY MARKET: REGIONAL MIX
4.4 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
4.5 INJECTABLE DRUG DELIVERY MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

5.1 MARKET DYNAMICS
- 5.1.1 DRIVERS
  - 5.1.1.1 Growing demand for self-injection devices
  - 5.1.1.2 Advancements in drug delivery technologies
  - 5.1.1.3 Rising prevalence of chronic diseases
  - 5.1.1.4 Growing adoption of biologics and biosimilars
- 5.1.2 RESTRAINTS
  - 5.1.2.1 Infections associated with needlestick injuries
  - 5.1.2.2 Stringent government regulations
- 5.1.3 OPPORTUNITIES
  - 5.1.3.1 Development of novel drug delivery systems
  - 5.1.3.2 Growing preference for home-based care devices
  - 5.1.3.3 Growth opportunities in emerging economies
- 5.1.4 CHALLENGES
  - 5.1.4.1 Alternative methods of drug delivery
  - 5.1.4.2 Complexities in developing wearable drug delivery systems
5.2 INDUSTRY TRENDS
- 5.2.1 REUSABLE DRUG DELIVERY DEVICES
- 5.2.2 PREFILLED BIOLOGICS
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
- 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  - 5.4.1.1 Average selling price trend of key players, by device type
  - 5.4.1.2 Average selling price trend of key players, by pen injectors
- 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
  - 5.4.2.1 Average selling price trend of pen injectors, by region
  - 5.4.2.2 Average selling price trend of needle-free injectors, by region
  - 5.4.2.3 Average selling price trend of autoinjectors, by region
  - 5.4.2.4 Average selling price trend of wearable injectors, by region
5.5 VALUE CHAIN ANALYSIS
- 5.5.1 RESEARCH & PRODUCT DEVELOPMENT
- 5.5.2 RAW MATERIAL PROCUREMENT
- 5.5.3 MANUFACTURING
- 5.5.4 MARKETING, SALES & DISTRIBUTION, AND AFTER-SALES SERVICES
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
  - 5.9.1.1 Autoinjectors and smart injection devices
  - 5.9.1.2 Needle-free injection systems and microneedle patches
  - 5.9.1.3 Wearable injectors for high-volume delivery
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
  - 5.9.2.1 Nanotechnology
  - 5.9.2.2 Biodegradable polymers
- 5.9.3 ADJACENT TECHNOLOGIES
  - 5.9.3.1 Artificial intelligence and digital therapeutics
  - 5.9.3.2 Alternative routes of administration
5.10 PATENT ANALYSIS
- 5.10.1 PATENT PUBLICATION TRENDS FOR INJECTABLE DRUG DELIVERY
- 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
5.11 TRADE ANALYSIS
- 5.11.1 TRADE DATA FOR HS CODE 901890
  - 5.11.1.1 Import data
  - 5.11.1.2 Export data
- 5.11.2 TRADE DATA FOR HS CODE 90183100
  - 5.11.2.1 Import data
  - 5.11.2.2 Export data
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
5.14 REGULATORY LANDSCAPE
- 5.14.1 REGULATORY ANALYSIS
- 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 PORTER'S FIVE FORCES ANALYSIS
- 5.15.1 BARGAINING POWER OF SUPPLIERS
- 5.15.2 BARGAINING POWER OF BUYERS
- 5.15.3 THREAT OF NEW ENTRANTS
- 5.15.4 THREAT OF SUBSTITUTES
- 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.16.1 KEY STAKEHOLDERS
- 5.16.2 BUYING CRITERIA
  - 5.16.2.1 Buying criteria for injectable drug delivery devices
  - 5.16.2.2 Buying criteria for injectable drug delivery devices with formulations
5.17 PIPELINE ANALYSIS
5.18 REIMBURSEMENT ANALYSIS
5.19 UNMET NEEDS/END-USER EXPECTATIONS
5.20 IMPACT OF AI/GEN AI IN INJECTABLE DRUG DELIVERY MARKET
- 5.20.1 INTRODUCTION
- 5.20.2 MARKET POTENTIAL OF AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
- 5.20.3 AI USE CASES
- 5.20.4 KEY COMPANIES IMPLEMENTING AI IN INJECTABLE DRUG DELIVERY DEVICES
- 5.20.5 FUTURE OF GEN AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
5.21 IMPACT OF 2025 US TARIFF
- 5.21.1 INTRODUCTION
- 5.21.2 KEY TARIFF RATES
- 5.21.3 PRICE IMPACT ANALYSIS
- 5.21.4 IMPACT ON COUNTRY/REGION
  - 5.21.4.1 North America
  - 5.21.4.2 Asia Pacific
  - 5.21.4.3 Europe
  - 5.21.4.4 Latin America
- 5.21.5 IMPACT ON END-USE INDUSTRIES

6 INJECTABLE DRUG DELIVERY, BY PRODUCT

6.1 INTRODUCTION
6.2 DEVICES
- 6.2.1 CONVENTIONAL INJECTION DEVICES
  - 6.2.1.1 By material
    - 6.2.1.1.1 Glass injectable devices
      - 6.2.1.1.1.1 Light protection, temperature resistance, and impermeability properties to drive market
    - 6.2.1.1.2 Plastic injectable devices
      - 6.2.1.1.2.1 Rapid increase in demand for syringes to aid growth
  - 6.2.1.2 By product
    - 6.2.1.2.1 Fillable syringes
      - 6.2.1.2.1.1 Ease of use and variable dosing formulations to boost market
    - 6.2.1.2.2 Prefilled syringes
      - 6.2.1.2.2.1 Minimal drug waste and low weight & space requirements to propel market
  - 6.2.1.3 By usability
    - 6.2.1.3.1 Reusable injection devices
      - 6.2.1.3.1.1 Cost-effective nature to contribute to growth
    - 6.2.1.3.2 Disposable injection devices
      - 6.2.1.3.2.1 Growing preference for ready-to-use devices to drive market
- 6.2.2 SELF-INJECTION DEVICES
  - 6.2.2.1 Needle-free injectors
    - 6.2.2.1.1 By product
      - 6.2.2.1.1.1 Fillable needle-free injectors
      - 6.2.2.1.1.2 Prefilled needle-free injectors
    - 6.2.2.1.2 By technology
      - 6.2.2.1.2.1 Jet-based needle-free injectors
      - 6.2.2.1.2.2 Spring-based needle-free injectors
      - 6.2.2.1.2.3 Laser-powered needle-free injectors
      - 6.2.2.1.2.4 Vibration-based needle-free injectors
    - 6.2.2.1.3 By usability
      - 6.2.2.1.3.1 Reusable needle-free injectors
      - 6.2.2.1.3.2 Disposable needle-free injectors
  - 6.2.2.2 Autoinjectors
    - 6.2.2.2.1 By product
      - 6.2.2.2.1.1 Fillable autoinjectors
      - 6.2.2.2.1.2 Prefilled autoinjectors
    - 6.2.2.2.2 By technology
      - 6.2.2.2.2.1 Automated autoinjectors
      - 6.2.2.2.2.2 Manual autoinjectors
    - 6.2.2.2.3 By design
      - 6.2.2.2.3.1 Standardized autoinjectors
      - 6.2.2.2.3.2 Customized autoinjectors
    - 6.2.2.2.4 By usability
      - 6.2.2.2.4.1 Reusable autoinjectors
      - 6.2.2.2.4.2 Disposable autoinjectors
  - 6.2.2.3 Pen injectors
    - 6.2.2.3.1 By product
      - 6.2.2.3.1.1 Single-chambered pen injectors
      - 6.2.2.3.1.2 Double-chambered pen injectors.
    - 6.2.2.3.2 By design
      - 6.2.2.3.2.1 Standard pen injectors
      - 6.2.2.3.2.2 Customized pen injectors
    - 6.2.2.3.3 By usability
      - 6.2.2.3.3.1 Reusable pen injectors
      - 6.2.2.3.3.2 Disposable pen injectors
  - 6.2.2.4 Wearable injectors
    - 6.2.2.4.1 Increasing need for safe and convenient injections to accelerate growth
  - 6.2.2.5 Other self-injection devices
6.3 FORMULATIONS
- 6.3.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
  - 6.3.1.1 Solutions
    - 6.3.1.1.1 High stability and sterility benefits to intensify growth
  - 6.3.1.2 Reconstituted/lyophilized formulations
    - 6.3.1.2.1 Higher suitability for parenteral administration to aid growth
  - 6.3.1.3 Suspensions
    - 6.3.1.3.1 Innovations in injectable suspensions for stable and sustained delivery to aid growth
  - 6.3.1.4 Emulsions
    - 6.3.1.4.1 Advancements in injectable emulsions for controlled and sustained drug delivery to drive market
- 6.3.2 NOVEL DRUG DELIVERY FORMULATIONS
  - 6.3.2.1 Colloidal dispersions
    - 6.3.2.1.1 Niosomes
      - 6.3.2.1.1.1 Low toxicity and economical features to speed up growth.
    - 6.3.2.1.2 Liposomes
      - 6.3.2.1.2.1 Flexible, biocompatible, and fully biodegradable properties to boost market
    - 6.3.2.1.3 Polymeric/mixed micelles
      - 6.3.2.1.3.1 Ability to deliver hydrophobic drugs with slower dissolution rates to boost market
    - 6.3.2.1.4 Nanoparticles
      - 6.3.2.1.4.1 Solid-lipid nanoparticles
      - 6.3.2.1.4.2 Nanosuspensions
      - 6.3.2.1.4.3 Nanoemulsions
  - 6.3.2.2 Microparticles
    - 6.3.2.2.1 Microspheres
      - 6.3.2.2.1.1 Growing focus of major pharmaceutical companies on microsphere drug delivery to drive market
    - 6.3.2.2.2 Microcapsules
      - 6.3.2.2.2.1 Higher biocompatibility properties to augment growth
- 6.3.3 LONG-ACTING INJECTABLE FORMULATIONS
  - 6.3.3.1 Decreased side effects and overall medical cost reduction to advance growth

7 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING

7.1 INTRODUCTION
7.2 AMPOULES
- 7.2.1 EASE OF TRANSPORTATION AND LOW MANUFACTURING COST TO AID GROWTH
7.3 VIALS
- 7.3.1 NEED FOR SECURE, DEPENDABLE, AND COST-EFFECTIVE CONTAINERS TO ENCOURAGE GROWTH
7.4 CARTRIDGES
- 7.4.1 INCREASING FOCUS ON DOSE ACCURACY AND PATIENT CONVENIENCE TO FACILITATE GROWTH
7.5 BOTTLES
- 7.5.1 RISING FOCUS ON SAFE STORAGE OF SOLUTIONS AND EMULSIONS TO FOSTER GROWTH

8 INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION

8.1 INTRODUCTION
8.2 AUTOIMMUNE DISEASES
- 8.2.1 RHEUMATOID ARTHRITIS
  - 8.2.1.1 Increased focus on early-stage diagnosis and treatment to amplify growth
- 8.2.2 MULTIPLE SCLEROSIS
  - 8.2.2.1 Increasing target patient pool to contribute to growth
- 8.2.3 CROHN'S DISEASE
  - 8.2.3.1 Rising use of liposomes to aid growth
- 8.2.4 PSORIASIS
  - 8.2.4.1 Lifestyle changes and high disease prevalence to support growth
- 8.2.5 OTHER AUTOIMMUNE DISEASES
8.3 HORMONAL DISORDERS
- 8.3.1 DIABETES
  - 8.3.1.1 Growing preference for self-injection devices over traditional syringes to drive market
- 8.3.2 REPRODUCTIVE HEALTH DISEASES
  - 8.3.2.1 Lack of healthcare facilities and hygiene practices to aid growth
- 8.3.3 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
  - 8.3.3.1 High efficacy and safety of heparin for antithrombotic therapy to aid growth
- 8.3.4 OSTEOPOROSIS
  - 8.3.4.1 Increasing number of women with calcium and vitamin D deficiencies to foster growth
- 8.3.5 GROWTH HORMONE DEFICIENCY
  - 8.3.5.1 Increased need for daily injections of recombinant human growth hormones to fuel market
8.4 OBESITY
- 8.4.1 CHANGING SEDENTARY LIFESTYLE AND CONSUMPTION OF OVER-PROCESSED FOODS TO AID GROWTH
8.5 CANCER
- 8.5.1 INCREASING LAUNCHES OF NEW VACCINES AND TARGETED THERAPIES TO BOLSTER GROWTH
8.6 INFECTIOUS DISEASES
- 8.6.1 GROWING ADVANCEMENTS IN INJECTABLE THERAPIES TO DRIVE MARKET
8.7 ORPHAN DISEASES
- 8.7.1 FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT GROWTH
8.8 OTHER THERAPEUTIC APPLICATIONS
- 8.8.1 PAIN MANAGEMENT
  - 8.8.1.1 Growing focus on treating chronic pain to drive market
- 8.8.2 ALLERGIES
  - 8.8.2.1 Increasing prevalence of asthma and eczema to promote growth
- 8.8.3 AESTHETIC TREATMENTS
  - 8.8.3.1 Growing popularity of aesthetic procedures to propel market
- 8.8.4 HEPATITIS C
  - 8.8.4.1 Need to curb virus spread due to needle reshare to sustain growth
- 8.8.5 HEMOPHILIA
  - 8.8.5.1 Increasing need for preventive treatment plans to assist growth

9 INJECTABLE DRUG DELIVERY, BY USAGE PATTERN

9.1 INTRODUCTION
9.2 CURATIVE CARE
- 9.2.1 RISE IN INFECTIOUS DISEASES TO ACCELERATE GROWTH
9.3 IMMUNIZATION
- 9.3.1 GROWING DEMAND FOR VACCINES FROM HEALTHCARE ORGANIZATIONS TO DRIVE MARKET
9.4 OTHER USAGE PATTERNS

10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION

10.1 INTRODUCTION
10.2 DERMAL-BASED ADMINISTRATION
- 10.2.1 RAPID AND EFFECTIVE METHOD WITH LOW PAIN TO AMPLIFY GROWTH
10.3 CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
- 10.3.1 HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT GROWTH
10.4 ORGAN-BASED ADMINISTRATION
- 10.4.1 GROWING UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST MARKET
10.5 CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
- 10.5.1 INCREASING FOCUS ON PAIN MANAGEMENT TO PROMOTE GROWTH

11 INJECTABLE DRUG DELIVERY MARKET, BY END USER

11.1 INTRODUCTION
11.2 HOSPITALS & CLINICS
- 11.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
11.3 HOME CARE SETTINGS
- 11.3.1 GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET
11.4 LONG-TERM CARE SETTINGS
- 11.4.1 BOOMING ELDERLY POPULATION AND BURDEN OF CHRONIC DISEASES TO EXPEDITE GROWTH
11.5 NURSING HOMES
- 11.5.1 GLOBAL SHIFT TOWARD AGED POPULATION TO STIMULATE GROWTH
11.6 OTHER END USERS

12 INJECTABLE DRUG DELIVERY MARKET, BY REGION

12.1 INTRODUCTION
12.2 NORTH AMERICA
- 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 12.2.2 US
  - 12.2.2.1 Increasing prevalence of chronic diseases to expedite growth
- 12.2.3 CANADA
  - 12.2.3.1 Growing preference for self-injection devices to drive market
12.3 EUROPE
- 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 12.3.2 GERMANY
  - 12.3.2.1 High healthcare spending to propel growth
- 12.3.3 UK
  - 12.3.3.1 Rising cases of obesity and diabetes to promote growth
- 12.3.4 FRANCE
  - 12.3.4.1 Favorable health insurance system to accelerate growth
- 12.3.5 SPAIN
  - 12.3.5.1 Favorable healthcare regulations support growth
- 12.3.6 ITALY
  - 12.3.6.1 Regional variation in terms of coverage and benefits to hinder growth
- 12.3.7 NETHERLANDS
  - 12.3.7.1 Growing focus on enhanced patient care to drive market
- 12.3.8 REST OF EUROPE
12.4 ASIA PACIFIC
- 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 12.4.2 CHINA
  - 12.4.2.1 Large patient population and healthcare infrastructure improvements to augment growth
- 12.4.3 JAPAN
  - 12.4.3.1 Supportive reimbursement policies and universal healthcare coverage to aid growth
- 12.4.4 INDIA
  - 12.4.4.1 Rising diabetes and cardiovascular disease burden to propel market
- 12.4.5 AUSTRALIA
  - 12.4.5.1 Increased patient volume to contribute to growth
- 12.4.6 SOUTH KOREA
  - 12.4.6.1 Rising incidence of obesity and hypertension to amplify growth
- 12.4.7 THAILAND
  - 12.4.7.1 Expanding self-administration options to support growth
- 12.4.8 VIETNAM
  - 12.4.8.1 Rising investments and regulatory reforms to support market growth
- 12.4.9 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
- 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 12.5.2 BRAZIL
  - 12.5.2.1 Surge in obesity issues to stimulate growth
- 12.5.3 MEXICO
  - 12.5.3.1 Increasing incidence of chronic diseases to drive market
- 12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
- 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 12.6.2 GCC COUNTRIES
  - 12.6.2.1 Saudi Arabia
    - 12.6.2.1.1 Healthcare reforms to contribute to growth
  - 12.6.2.2 United Arab Emirates (UAE)
    - 12.6.2.2.1 Growing infrastructure investments to drive market
  - 12.6.2.3 Rest of GCC Countries
- 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.3 REVENUE ANALYSIS, 2020-2024
- 13.3.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
- 13.3.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
13.4 MARKET SHARE ANALYSIS, 2024
- 13.4.1 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
- 13.4.2 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
13.5 BRAND/PRODUCT COMPARISON
13.6 R&D EXPENDITURE OF KEY PLAYERS
13.7 COMPANY VALUATION AND FINANCIAL METRICS
- 13.7.1 COMPANY VALUATION
- 13.7.2 FINANCIAL METRICS
13.8 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
- 13.8.1 STARS
- 13.8.2 EMERGING LEADERS
- 13.8.3 PERVASIVE PLAYERS
- 13.8.4 PARTICIPANTS
- 13.8.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT, 2024
  - 13.8.5.1 Company footprint
  - 13.8.5.2 Region footprint
  - 13.8.5.3 Product type footprint
  - 13.8.5.4 Usage pattern footprint
  - 13.8.5.5 Therapeutic application footprint
  - 13.8.5.6 Site of administration footprint
13.9 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
- 13.9.1 PROGRESSIVE COMPANIES
- 13.9.2 RESPONSIVE COMPANIES
- 13.9.3 DYNAMIC COMPANIES
- 13.9.4 STARTING BLOCKS
- 13.9.5 INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024
  - 13.9.5.1 Detailed list of key startups/SMEs
  - 13.9.5.2 Competitive benchmarking of startups/SMES
13.10 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
- 13.10.1 STARS
- 13.10.2 EMERGING LEADERS
- 13.10.3 PERVASIVE PLAYERS
- 13.10.4 PARTICIPANTS
- 13.10.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT, 2024
  - 13.10.5.1 Company footprint
  - 13.10.5.2 Region footprint
  - 13.10.5.3 Product type footprint
  - 13.10.5.4 Formulation packaging type footprint
  - 13.10.5.5 Therapeutic application footprint
  - 13.10.5.6 Site of administration footprint
13.11 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
- 13.11.1 PROGRESSIVE COMPANIES
- 13.11.2 RESPONSIVE COMPANIES
- 13.11.3 DYNAMIC COMPANIES
- 13.11.4 STARTING BLOCKS
- 13.11.5 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024
  - 13.11.5.1 Detailed list of key startups/SMEs
  - 13.11.5.2 Competitive benchmarking of startups/SMEs
13.12 COMPETITIVE SCENARIO
- 13.12.1 PRODUCT LAUNCHES AND APPROVALS
- 13.12.2 DEALS
- 13.12.3 EXPANSIONS

14 COMPANY PROFILES: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS

14.1 KEY PLAYERS
- 14.1.1 CARDINAL HEALTH
  - 14.1.1.1 Business overview
  - 14.1.1.2 Products offered
  - 14.1.1.3 Recent developments
    - 14.1.1.3.1 Expansions
  - 14.1.1.4 MnM view
    - 14.1.1.4.1 Right to win
    - 14.1.1.4.2 Strategic choices
    - 14.1.1.4.3 Weaknesses and competitive threats
- 14.1.2 BD
  - 14.1.2.1 Business overview
  - 14.1.2.2 Products offered
  - 14.1.2.3 Recent developments
    - 14.1.2.3.1 Deals
    - 14.1.2.3.2 Expansions
  - 14.1.2.4 MnM view
    - 14.1.2.4.1 Right to win
    - 14.1.2.4.2 Strategic choices
    - 14.1.2.4.3 Weaknesses and competitive threats
- 14.1.3 B. BRAUN SE
  - 14.1.3.1 Business overview
  - 14.1.3.2 Products offered
  - 14.1.3.3 MnM view
    - 14.1.3.3.1 Right to win
    - 14.1.3.3.2 Strategic choices
    - 14.1.3.3.3 Weaknesses and competitive threats
- 14.1.4 BAXTER
  - 14.1.4.1 Business overview
  - 14.1.4.2 Products offered
  - 14.1.4.3 Recent developments
    - 14.1.4.3.1 Product launches and approvals
  - 14.1.4.4 MnM view
    - 14.1.4.4.1 Right to win
    - 14.1.4.4.2 Strategic choices
    - 14.1.4.4.3 Weaknesses and competitive threats
- 14.1.5 TERUMO CORPORATION
  - 14.1.5.1 Business overview
  - 14.1.5.2 Products offered
  - 14.1.5.3 Recent developments
    - 14.1.5.3.1 Product launches and approvals
    - 14.1.5.3.2 Expansions
  - 14.1.5.4 MnM view
    - 14.1.5.4.1 Right to win
    - 14.1.5.4.2 Strategic choices
    - 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 PHILLIPS-MEDSIZE CORPORATION (MOLEX)
  - 14.1.6.1 Business overview
  - 14.1.6.2 Products offered
  - 14.1.6.3 Recent developments
    - 14.1.6.3.1 Product launches and approvals
    - 14.1.6.3.2 Deals
    - 14.1.6.3.3 Expansions
- 14.1.7 NIPRO
  - 14.1.7.1 Business overview
  - 14.1.7.2 Products offered
  - 14.1.7.3 Recent developments
    - 14.1.7.3.1 Expansions
- 14.1.8 ICU MEDICAL, INC.
  - 14.1.8.1 Business overview
  - 14.1.8.2 Products offered
  - 14.1.8.3 Recent developments
    - 14.1.8.3.1 Deals
- 14.1.9 WEST PHARMACEUTICAL SERVICES, INC.
  - 14.1.9.1 Business overview
  - 14.1.9.2 Products offered
  - 14.1.9.3 Recent developments
    - 14.1.9.3.1 Deals
    - 14.1.9.3.2 Expansions
- 14.1.10 GERRESHEIMER AG
  - 14.1.10.1 Business overview
  - 14.1.10.2 Products offered
  - 14.1.10.3 Recent developments
    - 14.1.10.3.1 Product launches and approvals
    - 14.1.10.3.2 Deals
    - 14.1.10.3.3 Expansions
- 14.1.11 STEVANATO
  - 14.1.11.1 Business overview
  - 14.1.11.2 Products offered
  - 14.1.11.3 Recent developments
    - 14.1.11.3.1 Product launches and approvals
    - 14.1.11.3.2 Deals
    - 14.1.11.3.3 Expansions
- 14.1.12 SCHOTT PHARMA
  - 14.1.12.1 Business overview
  - 14.1.12.2 Products offered
  - 14.1.12.3 Recent developments
    - 14.1.12.3.1 Product launches and approvals
    - 14.1.12.3.2 Deals
    - 14.1.12.3.3 Expansions
- 14.1.13 MEDMIX
  - 14.1.13.1 Business overview
  - 14.1.13.2 Products offered
  - 14.1.13.3 Recent developments
    - 14.1.13.3.1 Product launches and approvals
    - 14.1.13.3.2 Deals
- 14.1.14 SOLM
  - 14.1.14.1 Business overview
  - 14.1.14.2 Products offered
- 14.1.15 YPSOMED
  - 14.1.15.1 Business overview
  - 14.1.15.2 Products offered
  - 14.1.15.3 Recent developments
    - 14.1.15.3.1 Deals
    - 14.1.15.3.2 Expansions
14.2 OTHER PLAYERS
- 14.2.1 OWEN MUMFORD
- 14.2.2 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
- 14.2.3 POLYMEDICURE
- 14.2.4 UNION MEDICO INC.
- 14.2.5 SHL MEDICAL
- 14.2.6 ELCAM MEDICAL

15 COMPANY PROFILES: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS

15.1 KEY PLAYERS
- 15.1.1 JOHNSON & JOHNSON SERVICES, INC.
  - 15.1.1.1 Business overview
  - 15.1.1.2 Products offered
  - 15.1.1.3 Recent developments
    - 15.1.1.3.1 Product launches and approvals
    - 15.1.1.3.2 Deals
  - 15.1.1.4 MnM view
    - 15.1.1.4.1 Right to win
    - 15.1.1.4.2 Strategic choices
    - 15.1.1.4.3 Weaknesses and competitive threats
- 15.1.2 F. HOFFMANN-LA ROCHE LTD
  - 15.1.2.1 Business overview
  - 15.1.2.2 Products offered
  - 15.1.2.3 Recent developments
    - 15.1.2.3.1 Product launches and approvals
  - 15.1.2.4 MnM view
    - 15.1.2.4.1 Right to win
    - 15.1.2.4.2 Strategic choices
    - 15.1.2.4.3 Weaknesses and competitive threats
- 15.1.3 PFIZER INC.
  - 15.1.3.1 Business overview
  - 15.1.3.2 Products offered
  - 15.1.3.3 Recent developments
    - 15.1.3.3.1 Product launches and approvals
    - 15.1.3.3.2 Deals
  - 15.1.3.4 MnM view
    - 15.1.3.4.1 Right to win
    - 15.1.3.4.2 Strategic choices
    - 15.1.3.4.3 Weaknesses and competitive threats
- 15.1.4 MERCK & CO., INC.
  - 15.1.4.1 Business overview
  - 15.1.4.2 Products offered
  - 15.1.4.3 Recent developments
    - 15.1.4.3.1 Product launches and approvals
    - 15.1.4.3.2 Deals
    - 15.1.4.3.3 Expansions
  - 15.1.4.4 MnM view
    - 15.1.4.4.1 Right to win
    - 15.1.4.4.2 Strategic choices
    - 15.1.4.4.3 Weaknesses and competitive threats
- 15.1.5 NOVARTIS AG
  - 15.1.5.1 Business overview
  - 15.1.5.2 Products offered
  - 15.1.5.3 Recent developments
    - 15.1.5.3.1 Product launches and approvals
    - 15.1.5.3.2 Deals
    - 15.1.5.3.3 Expansions
  - 15.1.5.4 MnM view
    - 15.1.5.4.1 Right to win
    - 15.1.5.4.2 Strategic choices
    - 15.1.5.4.3 Weaknesses and competitive threats
- 15.1.6 BAYER AG
  - 15.1.6.1 Business overview
  - 15.1.6.2 Products offered
  - 15.1.6.3 Recent developments
    - 15.1.6.3.1 Product launches and approvals
    - 15.1.6.3.2 Expansions
- 15.1.7 ASTRAZENECA
  - 15.1.7.1 Business overview
  - 15.1.7.2 Products offered
  - 15.1.7.3 Recent developments
    - 15.1.7.3.1 Product launches and approvals
    - 15.1.7.3.2 Deals
    - 15.1.7.3.3 Expansions
- 15.1.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
  - 15.1.8.1 Business overview
  - 15.1.8.2 Products offered
  - 15.1.8.3 Recent developments
    - 15.1.8.3.1 Product launches and approvals
    - 15.1.8.3.2 Deals
    - 15.1.8.3.3 Expansions
- 15.1.9 ELI LILLY AND COMPANY
  - 15.1.9.1 Business overview
  - 15.1.9.2 Products offered
  - 15.1.9.3 Recent developments
    - 15.1.9.3.1 Product launches and approvals
    - 15.1.9.3.2 Expansions
- 15.1.10 AMGEN INC.
  - 15.1.10.1 Business overview
  - 15.1.10.2 Products offered
  - 15.1.10.3 Recent developments
    - 15.1.10.3.1 Product launches and approvals
    - 15.1.10.3.2 Deals
    - 15.1.10.3.3 Expansions
- 15.1.11 NOVO NORDISK A/S
  - 15.1.11.1 Business overview
  - 15.1.11.2 Products offered
  - 15.1.11.3 Recent developments
    - 15.1.11.3.1 Product launches and approvals
    - 15.1.11.3.2 Deals
    - 15.1.11.3.3 Expansions
- 15.1.12 REGENERON PHARMACEUTICALS INC.
  - 15.1.12.1 Business overview
  - 15.1.12.2 Products offered
    - 15.1.12.2.1 Product launches and approvals
    - 15.1.12.2.2 Deals
- 15.1.13 FRESENIUS KABI AG
  - 15.1.13.1 Business overview
  - 15.1.13.2 Products offered
  - 15.1.13.3 Recent developments
    - 15.1.13.3.1 Product launches and approvals
- 15.1.14 UCB S.A.
  - 15.1.14.1 Business overview
  - 15.1.14.2 Products offered
  - 15.1.14.3 Recent developments
    - 15.1.14.3.1 Product launches and approvals
- 15.1.15 BIO-THERA SOLUTIONS, LTD.
  - 15.1.15.1 Business overview
  - 15.1.15.2 Products offered
  - 15.1.15.3 Recent developments
    - 15.1.15.3.1 Product launches and approvals
15.2 OTHER PLAYERS
- 15.2.1 SAGENT
- 15.2.2 VALNEVA SE
- 15.2.3 XERIS PHARMACEUTICALS, INC.
- 15.2.4 PHARMAESSENTIA CORPORATION
- 15.2.5 HERON THERAPEUTICS, INC.

16 APPENDIX

16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
16.3 RELATED REPORTS
16.4 AUTHOR DETAILS

注射用ドラッグデリバリーの世界市場：製品別、剤形パッケージング別、治療用途別、使用パターン別、投与部位別、エンドユーザー別、地域別 - 2030年までの予測

Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030

目次

第1章イントロダクション

第2章調査手法

第3章エグゼクティブサマリー

第4章重要考察

第5章市場概要

第6章注射用ドラッグデリバリー市場、製品別

第7章注射用ドラッグデリバリー市場、剤形パッケージング別

第8章注射用ドラッグデリバリー市場、治療用途別

第9章注射用ドラッグデリバリー市場、使用パターン別

第10章注射用ドラッグデリバリー市場、投与部位別

第11章注射用ドラッグデリバリー市場、エンドユーザー別

第12章注射用ドラッグデリバリー市場、地域別

第13章競合情勢

第14章企業プロファイル：注射用ドラッグデリバリーデバイスメーカー

第15章企業プロファイル：注射用ドラッグデリバリー製剤メーカー

第16章付録

List of Tables

List of Figures

This report provides insights into the following points:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 INJECTABLE DRUG DELIVERY, BY PRODUCT

7 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING

8 INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION

9 INJECTABLE DRUG DELIVERY, BY USAGE PATTERN

10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION

11 INJECTABLE DRUG DELIVERY MARKET, BY END USER

12 INJECTABLE DRUG DELIVERY MARKET, BY REGION

13 COMPETITIVE LANDSCAPE

14 COMPANY PROFILES: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS

15 COMPANY PROFILES: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS

16 APPENDIX

注射用ドラッグデリバリーの世界市場：製品別、剤形パッケージング別、治療用途別、使用パターン別、投与部位別、エンドユーザー別、地域別 - 2030年までの予測

Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

第6章 注射用ドラッグデリバリー市場、製品別

第7章 注射用ドラッグデリバリー市場、剤形パッケージング別

第8章 注射用ドラッグデリバリー市場、治療用途別

第9章 注射用ドラッグデリバリー市場、使用パターン別

第10章 注射用ドラッグデリバリー市場、投与部位別

第11章 注射用ドラッグデリバリー市場、エンドユーザー別

第12章 注射用ドラッグデリバリー市場、地域別

第13章 競合情勢

第14章 企業プロファイル：注射用ドラッグデリバリーデバイスメーカー

第15章 企業プロファイル：注射用ドラッグデリバリー製剤メーカー

第16章 付録

List of Tables

List of Figures

This report provides insights into the following points:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 INJECTABLE DRUG DELIVERY, BY PRODUCT

7 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING

8 INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION

9 INJECTABLE DRUG DELIVERY, BY USAGE PATTERN

10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION

11 INJECTABLE DRUG DELIVERY MARKET, BY END USER

12 INJECTABLE DRUG DELIVERY MARKET, BY REGION

13 COMPETITIVE LANDSCAPE

14 COMPANY PROFILES: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS

15 COMPANY PROFILES: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS

16 APPENDIX

第1章イントロダクション

第2章調査手法

第3章エグゼクティブサマリー

第4章重要考察

第5章市場概要

第6章注射用ドラッグデリバリー市場、製品別

第7章注射用ドラッグデリバリー市場、剤形パッケージング別

第8章注射用ドラッグデリバリー市場、治療用途別

第9章注射用ドラッグデリバリー市場、使用パターン別

第10章注射用ドラッグデリバリー市場、投与部位別

第11章注射用ドラッグデリバリー市場、エンドユーザー別

第12章注射用ドラッグデリバリー市場、地域別

第13章競合情勢

第14章企業プロファイル：注射用ドラッグデリバリーデバイスメーカー

第15章企業プロファイル：注射用ドラッグデリバリー製剤メーカー

第16章付録